{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-043487","form_type":"8-K","ticker":"LRMR","cik":"0001374690","company_name":"Larimar Therapeutics, Inc.","filed_at":"2025-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.463978+00:00","generated_at":"2026-05-24T06:23:32.754143+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Larimar reports FDA open to FXN as surrogate endpoint; BLA submission on track for end-2025","bullets":["FDA considers skin FXN concentration reasonably likely surrogate endpoint for accelerated approval of nomlabofusp in Friedreich's ataxia.","BLA submission for accelerated approval targeted by year-end 2025; global Phase 3 study to initiate mid-2025.","Net loss of $28.8M in Q4 2024 ($0.45/share) vs. $13.0M ($0.30/share) in Q4 2023; R&D expenses rose to $26.7M.","Cash and equivalents $183.5M as of Dec 31, 2024; projected runway into Q2 2026.","OLE study amended to include premedication after anaphylaxis deemed adverse drug reaction; 50 mg data expected Sept 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-043487","json":"https://secwatch.observer/filing/0000950170-25-043487.json","markdown":"https://secwatch.observer/filing/0000950170-25-043487.md","text":"https://secwatch.observer/filing/0000950170-25-043487.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374690/000095017025043487/0000950170-25-043487-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374690/000095017025043487/lrmr-20250324.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T06:23:32.754143+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}